Quantification of the influenza virus load by real-time polymerase chain reaction in nasopharyngeal swabs of patients treated with oseltamivir

Journal of Infectious Diseases

Volumn 188, Issue 4, 2003, Pages 578-580

  Boivin, Guy ^a   Coulombe, Zoé ^a   Wat, Cynthia ^b  

^a LAVAL UNIVERSITY   (Canada)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILL; COMMON COLD; CONTROLLED STUDY; COUGHING; FATIGUE; FEVER; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; MYALGIA; NOSE SMEAR; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SORE THROAT; SWEATING; SYMPTOM; THROAT CULTURE; VIRUS LOAD; VIRUS REPLICATION;

ACETAMIDES; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASOPHARYNX; OSELTAMIVIR; POLYMERASE CHAIN REACTION; VIRAL LOAD;

EID: 0042943021     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377046     Document Type: Article

References (14)

1. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874-80.
2. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40:42-8.
3. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000; 355:1845-50.
4. Mist Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352:1877-81.
5. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-24.
6. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
7. Boivin G, Osterhaus AD, Gaudreau A, Jackson HC, Groen J, Ward P. Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection. J Clin Microbiol 2002; 40:330-4.
8. Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997; 35:2076-82.
9. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J Clin Invest 1998; 101:643-9.
10. Wright PF, Webster RG. Orthomyxoviruses. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001; 1533-79.
11. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000; 181:1471-4.
12. Boivin G, Hardy I, Kress A. Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA Test) in comparison with cell culture and reverse transcription-PCR. J Clin Microbiol 2001; 39:730-2.
13. Schweiger B, Zadow I, Heckler R, Timm H, Pauli G. Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J Clin Microbiol 2000; 38:1552-8.
14. Cherian T, Bobo L, Steinhoff MC, Karron RA, Yolken RH. Use of PCR-enzyme immunoassay for identification of influenza A virus matrix RNA in clinical samples negative for cultivable virus. J Clin Microbiol 1994; 32:623-8.